Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

97.95 +2.30 (+2.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 702,853
Open 98.25
Bid (Size) 97.95 (3,200)
Ask (Size) 98.04 (100)
Prev. Close 95.65
Today's Range 96.21 - 98.63
52wk Range 36.88 - 109.28
Shares Outstanding 38,297,975
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Mirum (MIRM) Q2 2025 Earnings Call Transcript ↗
Mirum (MIRM) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Mirum Pharma (MIRM) Earnings Call Transcript ↗
Mirum Pharma (MIRM) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings

Performance

YTD
+25.5%
+25.5%
1 Month
+10.3%
+10.3%
3 Month
+28.1%
+28.1%
6 Month
+32.8%
+32.8%
1 Year
+138.9%
+138.9%

More News

Read More
News headline image
Mirum (MIRM) Q1 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Intellectual Property
Mirum Pharmaceuticals (NASDAQ:MIRM) Reports Q4 2025 Revenue Beat and 2026 Outlook ↗
Via Chartmill
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Embodies the Minervini Growth Momentum Strategy ↗
Via Chartmill
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup ↗
Via Chartmill
News headline image
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗
Via The Motley Fool
News headline image
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗
Via The Motley Fool
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Small-Cap Shudder: Russell 2000’s 1.9% Slide Signals Cracks in Economic Resilience
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum (MIRM) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
ACM Research’s AI Surge Collides With Export Controls and Chip Spending Cycles ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Is Mirum Pharmaceuticals on a Strong Path to Profitability? ↗
Via The Motley Fool
News headline image
Is Mirum Pharmaceuticals About to Soar in 2026? ↗
Via The Motley Fool

Frequently Asked Questions

Is Mirum Pharmaceuticals, Inc. - common stock publicly traded?
Yes, Mirum Pharmaceuticals, Inc. - common stock is publicly traded.
What exchange does Mirum Pharmaceuticals, Inc. - common stock trade on?
Mirum Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Mirum Pharmaceuticals, Inc. - common stock?
The ticker symbol for Mirum Pharmaceuticals, Inc. - common stock is MIRM on the Nasdaq Stock Market
What is the current price of Mirum Pharmaceuticals, Inc. - common stock?
The current price of Mirum Pharmaceuticals, Inc. - common stock is 97.95
When was Mirum Pharmaceuticals, Inc. - common stock last traded?
The last trade of Mirum Pharmaceuticals, Inc. - common stock was at 04/08/26 04:00 PM ET
What is the market capitalization of Mirum Pharmaceuticals, Inc. - common stock?
The market capitalization of Mirum Pharmaceuticals, Inc. - common stock is 3.75B
How many shares of Mirum Pharmaceuticals, Inc. - common stock are outstanding?
Mirum Pharmaceuticals, Inc. - common stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.